ProMIS Neurosciences, Inc. (NASDAQ:PMN – Get Rating)'s stock price traded up 1.3% on Friday . The company traded as high as $6.08 and last traded at $6.08. 818 shares were traded during mid-day trading, a decline of 76% from the average session volume of 3,468 shares. The stock had previously closed at $6.00.
ProMIS Neurosciences Trading Up 1.3 %
The firm has a market capitalization of $52.16 million, a PE ratio of -3.32 and a beta of 0.64. The company has a 50-day simple moving average of $5.81.
Get ProMIS Neurosciences alerts:Hedge Funds Weigh In On ProMIS Neurosciences
An institutional investor recently bought a new position in ProMIS Neurosciences stock. Ieq Capital LLC purchased a new position in shares of ProMIS Neurosciences, Inc. (NASDAQ:PMN – Get Rating) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 39,191 shares of the company's stock, valued at approximately $240,000. Ieq Capital LLC owned 0.46% of ProMIS Neurosciences at the end of the most recent quarter. Institutional investors own 0.14% of the company's stock.
ProMIS Neurosciences Company Profile
(Get Rating)ProMIS Neurosciences, Inc discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.
See Also
- Get a free copy of the StockNews.com research report on ProMIS Neurosciences (PMN)
- MarketBeat: Week in Review 11/14 – 11/18
- Target's Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Verra Mobility Stock Has Returned Back to the Station
- Does ASML's November Rally Have Staying Power?
Receive News & Ratings for ProMIS Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMIS Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.